Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

Serum albumin is associated with clinical outcomes in patients with cancers. In a single-center retrospective study of 210 advanced NSCLC patients receiving immune checkpoint inhibitor (ICI) with or without chemotherapy as first-line therapy, we found a significant association of overall survival with pretreatment albumin and early albumin decrease in treatment with ICI monotherapy but not with chemoimmunotherapy. Background: Cancer cachexia exhibits decreased albumin and associates with short overall survival (OS) in patients with non-small cell lung cancer (NSCLC), but whether on-treatment albumin changes associate with OS in NSCLC patients treated with immune checkpoint inhibitors (ICIs) and combination chemoimmunotherapy has not been thoroughly evaluated. Patients and Methods: We conducted a single-center retrospective study of patients with advanced NSCLC who received first-line ICI with or without chemotherapy between 2013 and 2020. The association of pretreatment albumin and early albumin changes with OS was evaluated using Kaplan-Meier method and Cox regression models. Results: A total of 210 patients were included: 109 in ICI cohort and 101 in ICI + Chemo cohort. Within a median of 21 days from treatment initiation, patients with > 10% of albumin decrease had significantly shorter OS compared to patients without albumin decrease in ICI cohort. Pretreatment albumin and albumin decrease within the first or second cycle of treatment were significantly and independently associated with OS in ICI cohort, but not in ICI + Chemo cohort. The lack of association between albumin and OS with the addition of chemotherapy was more pronounced among patients with >= 1% PD-L1 expression in subgroup analysis. Conclusion: Pretreatment serum albumin and early albumin decrease in ICI monotherapy was significantly associated with OS in advanced NSCLC. Early albumin change, as a routine lab value tested in clinic, may be combined with established biomarkers to improve outcome predictions of ICI monotherapy. The underlying mechanism of the observed association between decreased albumin and ICI resistance warrants further investigation. (C) 2022 The Authors. Published by Elsevier Inc.

Automated summary

Serum albumin and early albumin decrease are significantly associated with overall survival in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy. This study suggests that albumin changes may serve as potential biomarkers to predict treatment outcomes and warrant further investigation.